Gradient Investments LLC Grows Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Gradient Investments LLC boosted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 168,972 shares of the medical equipment provider’s stock after acquiring an additional 8,787 shares during the quarter. Gradient Investments LLC owned 0.08% of Zimmer Biomet worth $17,849,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of ZBH. CX Institutional raised its holdings in Zimmer Biomet by 171.9% during the 4th quarter. CX Institutional now owns 2,336 shares of the medical equipment provider’s stock valued at $247,000 after buying an additional 1,477 shares during the last quarter. Brighton Jones LLC purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at about $204,000. Dakota Wealth Management raised its stake in shares of Zimmer Biomet by 1.3% during the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider’s stock valued at $1,016,000 after acquiring an additional 122 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Zimmer Biomet by 1.2% during the fourth quarter. Nisa Investment Advisors LLC now owns 63,099 shares of the medical equipment provider’s stock worth $6,680,000 after purchasing an additional 729 shares during the period. Finally, Roberts Wealth Advisors LLC bought a new stake in shares of Zimmer Biomet in the fourth quarter worth about $1,954,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Down 0.2 %

Shares of NYSE ZBH opened at $110.78 on Friday. The company has a market cap of $22.05 billion, a PE ratio of 21.06, a P/E/G ratio of 1.88 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The firm’s 50 day moving average price is $107.89 and its 200-day moving average price is $108.09. Zimmer Biomet Holdings, Inc. has a 52-week low of $100.67 and a 52-week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.65 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is presently 18.25%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ZBH. Evercore ISI dropped their price objective on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Wells Fargo & Company raised their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Raymond James reduced their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Finally, BTIG Research lowered their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $124.11.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.